The efficacy and safety of liraglutide as adjunct therapy to insulin in the treatment of type 1 diabetes. A 52-week randomised, treat-to-target, placebo-controlled, double-blinded, parallel-group, multinational, multi-centre trial

Trial Profile

The efficacy and safety of liraglutide as adjunct therapy to insulin in the treatment of type 1 diabetes. A 52-week randomised, treat-to-target, placebo-controlled, double-blinded, parallel-group, multinational, multi-centre trial

Completed
Phase of Trial: Phase III

Latest Information Update: 08 Mar 2017

At a glance

  • Drugs Liraglutide (Primary) ; Insulin
  • Indications Type 1 diabetes mellitus
  • Focus Registrational; Therapeutic Use
  • Acronyms ADJUNCT-ONE
  • Sponsors Novo Nordisk
  • Most Recent Events

    • 07 Jun 2017 Biomarkers information updated
    • 20 Dec 2016 Primary endpoint (Change from baseline in body weight) has been met.
    • 20 Dec 2016 Primary endpoint (Change from baseline in total daily insulin dose) has not been met for 0.6 mg liraglutide as adjunct to insulin therapy
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top